StonvexLoading…
StonvexStonvexStonvexCore line items from MRNA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $1.94B | $3.24B | $6.85B | $19.26B |
Operating Income | $-3.07B | $-3.94B | $-4.24B | $9.42B |
Net Income | $-2.82B | $-3.56B | $-4.71B | $8.36B |
EPS (Diluted) | $-7.26 | $-9.28 | $-12.33 | $20.12 |
Total Assets | $12.34B | $14.14B | $18.43B | $25.86B |
Total Liabilities | $3.69B | $3.24B | $4.57B | $6.74B |
Cash & Equivalents | $2.60B | $1.93B | $2.91B | $3.21B |
Free Cash Flow OCF − CapEx | $-2.06B | $-4.05B | $-3.83B | $4.58B |
Shares Outstanding | 394.00M | 386.00M | 382.00M | 385.00M |